Drug intelligence / Profile preview

ibuprofen + hydrocodone + acetaminophen + omeprazole

Development stage: Unknown
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **ibuprofen**, a nonsteroidal anti-inflammatory drug (NSAID) used for pain relief and inflammation; **hydrocodone**, an opioid analgesic used for severe pain; **acetaminophen**, a pain reliever and fever reducer; and **omeprazole**, a proton pump inhibitor used to treat acid reflux and stomach ulcers. The combination is likely intended to manage pain and protect the stomach lining, but it is not a standard formulation and should be used under medical supervision.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MOR (Mu opioid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on ibuprofen + hydrocodone + acetaminophen + omeprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + hydrocodone + acetaminophen + omeprazole.

Explore the full profile